A novel diagnostic tool leveraging AI for protein design and microfluidics for better cell therapy management

一种利用人工智能进行蛋白质设计和微流体技术以实现更好的细胞治疗管理的新型诊断工具

• 批准号: 10082156
• 金额: $ 41.27万
• 依托单位: BEYOND BLOOD DIAGNOSTICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10082156
• 关键词: novel; diagnostic; tool; leveraging; AI

A vital part of cancer cell therapy is to ensure that cells fighting the cancer (called T-cells) don't lose their ability to fight cancer cells or infections, a dysfunctional state called T-cell exhaustion. T-cell exhaustion plays a crucial role in the failure of cancer cell therapy. However, current hospitals and pharma companies lack the means to measure T-cell exhaustion, highlighting the need for new tools that can aid in treatment decisions.Doctors need easy to use tools that enable them to monitor if a patient's immune system becomes dysfunctional due to T-cell exhaustion, as they could prescribe a class of drugs called ICI that reverse T-cell exhaustion. This significant improvement in clinical practice would facilitate the efficient identification of patients who may require changes in treatment plans before the therapy starts to fail.Furthermore, pharma companies need extensive tests to monitor the patients enrolled in clinical trials in order to select them for enrollment, stratify them into groups and monitor how they respond to treatment. Consequently, there is a need to have clinical tests that monitor if a patient's immune system becomes dysfunctional during CAR-T cell therapy.The project brings together the expertise and components required for a next-generation lab-on-chip technology. By incorporating unique proteins designed by a German startup on a biochip, the project aims to automatically analyse T-cell activity, enabling the development of a cutting-edge test for T-cell exhaustion.This application is presented by a company in the UK developing biochips that analyse blood automatically. They have an opportunity to work with a German company using AI to develop new proteins - their AI platform identified proteins capable of tagging exhausted T-cells. These proteins exhibit high accuracy in tagging cells, yielding results in just 15 minutes. The successful integration of these technologies presents a significant market opportunity, estimated at £5.17 billion by 2032\.The two companies wish to work together on an industrial research project to modify the biochip developed in the UK and enable the use of these new proteins designed in Germany for automated tests.The enclosed team is seeking Innovate UK investment to conduct a programme of biomedical engineering and software-based research needed to enable the team to prove the biochip can be automated for rapid tests in CAR-T cell therapy.

癌细胞治疗的一个重要部分是确保对抗癌症的细胞（称为 T 细胞）不会失去对抗癌细胞或感染的能力，一种称为 T 细胞耗竭的功能失调状态起着至关重要的作用。然而，目前的医院和制药公司缺乏测量 T 细胞耗竭的方法，这凸显了对有助于治疗决策的新工具的需求。医生需要易于使用的工具来进行监测。如果患者的免疫系统变得由于 T 细胞耗竭而导致功能障碍，他们可以开出一类名为 ICI 的药物来逆转 T 细胞耗竭，这一临床实践的重大改进将有助于在治疗开始之前有效识别可能需要改变治疗计划的患者。此外，制药公司需要进行广泛的测试来监测参加临床试验的患者，以便选择他们进行注册，将他们分组并监测他们对治疗的反应，因此需要进行临床测试来监测是否会失败。患者的免疫系统变得该项目汇集了下一代芯片实验室技术所需的专业知识和组件，通过将一家德国初创公司设计的独特蛋白质整合到生物芯片上，该项目旨在自动分析 T-细胞。该应用程序由英国一家开发自动分析血液的生物芯片的公司提出，他们有机会与一家使用人工智能的德国公司合作开发新的。蛋白质 - 它们的人工智能平台鉴定出能够标记耗尽的 T 细胞的蛋白质。这些蛋白质在标记细胞方面表现出很高的准确性，只需 15 分钟即可得出结果。这些技术的成功整合带来了巨大的市场机会，预计到 2032 年价值将达到 51.7 亿英镑。这两者。公司希望共同开展一个工业研究项目，以修改在英国开发的生物芯片，并能够使用在德国设计的这些新蛋白质进行自动化测试。该团队正在寻求创新英国的投资，以开展生物医学工程和项目团队需要进行基于软件的研究来证明生物芯片可以自动化进行 CAR-T 细胞疗法的快速测试。